Skip to Main Content
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • Annual Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact
  • About
    • Staff
    • Board of Directors
    • Member Directory
  • Membership
    • Membership Benefits
    • Membership FAQ
    • Join NEC
  • Issues
    • Diversity & Inclusion
    • Energy & Environment
    • Financial Services
    • Healthcare
    • Higher Education
    • Technology & Innovation
    • Trade
    • Transportation & Infrastructure
    • Partnerships for Talent Pipeline Directory
  • News
  • Events
    • Upcoming Events
    • Past Events
    • Annual Celebration
    • Washington Leaders’ Conference
    • Politics & Eggs
    • Sponsorship Opportunities
  • Contact

News

Blog | Member News

EQRx Goes Public in $1.8 Billion Deal, Plans to Lower Drug Costs

EQRxs Alexis Borisy and Melanie Nallicheri pose for a portrait inside their office in Cambridge, MA
Image by Jessica Rinaldi/The Boston Globe

Pharmaceutical startup company and NEC member EQRx has gone public by raising $1.8 billion through a merger with a special purpose acquisition company (SPAC). The deal will advance EQRx’s “New Pharma” platform which aims to drastically lower drug prices.

EQRx will merge with CM Life Sciences III, a SPAC affiliated with Casdin Capital and Corvex Management, which will boost the pharmaceutical company’s value to $3.65. billion. This deal comes less than two years after the company was founded. In its future vision, EQRx plans to create medicines for known disease targets and license programs from other health-related companies in order to decrease the overall cost of development and increase the odds of gaining regulatory approval. Similarly, it plans to better understand the needs of the market by partnering with various health systems and insurers.

EQRx President, COO and future CEO Melanie Nallicheri is optimistic of the company’s future. “We are moving rapidly toward the potential commercialization of our lead oncology programs while continuing to group our pipeline to address the high-cost disease areas of today and in the future,” Nallicheri said.

The New England Council celebrates EQRx’s expansion and vision to make important medicines more affordable.

Read more in the Boston Globe.

Council Related News
Read Article Blog | Member News, Healthcare

Mass General and Brigham and Women’s rank among best hospitals in the country

Read Article Blog | Member News, Diversity & Inclusion, Healthcare

Dana-Farber doctor tapped to lead National Cancer Institute

Read Article Blog | Member News, Financial Services

Robinhood Hosts Financial Literacy Event in Boston

Read Article Blog | Member News, Energy & Environment, Technology & Innovation, Transportation & Infrastructure

Human-occupied submersible ‘Alvin’ makes historic dive

Read Article Blog | Member News, Diversity & Inclusion

National Grid supports development of Long Island’s first LGBT Chamber of Commerce

View Related News

©2022 New England Council
All rights reserved.

Privacy Policy Website Design by Jackrabbit

Boston Office

98 North Washington Street
Suite 303
Boston, MA 02114

(617) 723-4009

necouncil@newenglandcouncil.com

Washington Office

1411 K Street. NW
Suite 700
Washington, D.C. 20005

(202) 547-0048

necouncil@newenglandcouncil.com

Website Design by Jackrabbit